First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Li, Ying ^a   Wang, Lin Run ^a   Chen, Jian ^a   Lou, Yan ^a   Zhang, Guo Bing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1 SUBUNIT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN, HUMAN; DEOXYCYTIDINE; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; RRM1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHEMOSENSITIVITY; CHINESE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; VERY ELDERLY; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84893744992     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/960458     Document Type: Review

References (15)

1. Jing Y. F., Wang Y., The development of predicting the lung cancer prognosis and resistance to gemcitabine by the expression level of RRM1. Journal of Clinical Pulmonary Medicine 2008 13 1268 1270
2. Rosell R., Danenberg K. D., Alberola V., Bepler G., Sanchez J. J., Camps C., Provencio M., Isla D., Taron M., Diz P., Artal A., Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical Cancer Research 2004 10 4 1318 1325 2-s2.0-12144285914 10.1158/1078-0432.CCR-03-0156 (Pubitemid 38365223)
3. Rosell R., Felip E., Taron M., Majo J., Mendez P., Sanchez-Ronco M., Queralt C., Sanchez J. J., Maestre J., Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clinical Cancer Research 2004 10 12 4215 4219 2-s2.0-3042665933 10.1158/1078-0432.CCR-040006 (Pubitemid 38812449)
4. Olaussen K. A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., Taranchon E., Filipits M., Pirker R., Popper H. H., Stahel R., Sabatier L., Pignon J.-P., Tursz T., Le Chevalier T., Soria J.-C., DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. The New England Journal of Medicine 2006 355 10 983 991 2-s2.0-33748435058 10.1056/NEJMoa060570 (Pubitemid 44343542)
5. Olaussen K. A., Fouret P., Kroemer G., ERCC1-specific immunostaining in non-small-cell lung cancer. The New England Journal of Medicine 2007 357 15 1559 1561 2-s2.0-35248874798 10.1056/NEJMc072007
6. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M. S., Queralt C., Majo J., Sanchez J. M., Sanchez J. J., Maestre J., BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics 2004 13 20 2443 2449 2-s2.0-19544379515 10.1093/hmg/ddh260 (Pubitemid 39377848)
7. Rosell R., Skrzypski M., Jassem E., Taron M., Bartolucci R., Sanchez J. J., Mendez P., Chaib I., Perez-Roca L., Szymanowska A., Rzyman W., Puma F., Kobierska-Gulida G., Farabi R., Jassem J., BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007 2 11, article e1129 2-s2.0-42549088992 10.1371/journal.pone.0001129 (Pubitemid 351594028)
8. Wang L.-R., Zhang G.-B., Chen J., Li J., Li M.-W., Xu N., Wang Y., Shen Tu J.-Z., RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum. Journal of Zhejiang University B 2011 12 3 174 179 2-s2.0-79954507728 10.1631/jzus.B1000197
9. Wang L. R., Huang M. Z., Zhang G. B., Xu N., Wu X. H., Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 2007 60 4 601 607 2-s2.0-34447532355 10.1007/s00280-007-0504-x (Pubitemid 47084272)
10. Wang L. R., Wu X. H., Huang M. Z., Cai J., Xu N., Liu J., The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 2007 60 2 211 218 2-s2.0-34248396059 10.1007/s00280-006-0363-x (Pubitemid 46742536)
11. Rosell R., Danenberg K. D., Alberola V., Bepler G., Sanchez J. J., Camps C., Provencio M., Isla D., Taron M., Diz P., Artal A., Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical Cancer Research 2004 10 4 1318 1325 2-s2.0-12144285914 10.1158/1078-0432.CCR-03-0156 (Pubitemid 38365223)
12. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K. D., Danenberg P. V., Cambieri A., Selvaggi G., Saviozzi S., Calogero R., Papotti M., Scagliotti G. V., ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Annals of Oncology 2006 17 12 1818 1825 2-s2.0-33845361135 10.1093/annonc/mdl300 (Pubitemid 44884058)
13. Bergman A. M., Eijk P. P., Ruiz Van Haperen V. W. T., Smid K., Veerman G., Hubeek I., Van Den Ijssel P., Ylstra B., Peters G. J., In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Research 2005 65 20 9510 9516 2-s2.0-27144524050 10.1158/0008-5472.CAN-05-0989 (Pubitemid 41508021)
14. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., Simon G., RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. Journal of Clinical Oncology 2006 24 29 4731 4737 2-s2.0-33750579074 10.1200/JCO.2006.06.1101 (Pubitemid 46646245)
15. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M. S., Queralt C., Majo J., Sanchez J. M., Sanchez J. J., Maestre J., BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics 2004 13 20 2443 2449 2-s2.0-19544379515 10.1093/hmg/ddh260 (Pubitemid 39377848)